110 related articles for article (PubMed ID: 24246123)
1. Two cases of recurrent priapism during antineoplastic chemotherapy: think about ondansetron.
Pivot D; Javot L; Swiegot D; Petitpain N; Spaëth D; Trechot P
Therapie; 2013; 68(6):409-10. PubMed ID: 24246123
[No Abstract] [Full Text] [Related]
2. Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.
Lee CY; Ratnapalan S; Thompson M; Nathan PC; Closs J; French A; Punnett A; Garcia-Bournissen F; Ito S; Koren G
Can J Clin Pharmacol; 2010; 17(1):e1-4. PubMed ID: 20051608
[TBL] [Abstract][Full Text] [Related]
3. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
[TBL] [Abstract][Full Text] [Related]
4. Ondansetron to prevent vomiting after cancer chemotherapy.
Med Lett Drugs Ther; 1991 Jun; 33(847):63-4. PubMed ID: 1828531
[No Abstract] [Full Text] [Related]
5. [Anti-5-HT-3: a new group of antiemetics].
Galindo JR
Rev Clin Esp; 1996 Feb; 196(2):119-24. PubMed ID: 8685484
[No Abstract] [Full Text] [Related]
6. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
Abali H; Celik I
Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy-induced emesis and serotonin antagonists].
Jantunen I; Johansson R
Duodecim; 1991; 107(14):1112-5. PubMed ID: 1670506
[No Abstract] [Full Text] [Related]
8. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
9. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Goldsmith B
Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626
[No Abstract] [Full Text] [Related]
10. Nonischaemic priapism associated with selective serotonin-3 receptor antagonist.
Kilciler G; Kilciler M; Kadihasanoglu M; Atahan O
Andrologia; 2017 Aug; 49(6):. PubMed ID: 27709642
[TBL] [Abstract][Full Text] [Related]
11. Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting.
Rosow CE; Haspel KL; Smith SE; Grecu L; Bittner EA
Anesth Analg; 2008 May; 106(5):1407-9, table of contents. PubMed ID: 18420852
[TBL] [Abstract][Full Text] [Related]
12. Extrapyramidal reaction caused by ondansetron.
Mathews HG; Tancil CG
Ann Pharmacother; 1996 Feb; 30(2):196. PubMed ID: 8835061
[No Abstract] [Full Text] [Related]
13. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
14. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
[TBL] [Abstract][Full Text] [Related]
15. Ondansetron: reasons to be restrictive.
Frigerio C; Buchwalder PA; Spertini F
Lancet; 1996 May; 347(9013):1484-5. PubMed ID: 8676652
[No Abstract] [Full Text] [Related]
16. Recurrent bowel occlusion with oral ondansetron with no side effects of the intravenous route: a previously unknown adverse event.
Lebrun C; Chichmanian RM; Peyrade F; Chatel M; Frenay M
Ann Oncol; 1997 Sep; 8(9):919-20. PubMed ID: 9358948
[No Abstract] [Full Text] [Related]
17. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S
Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114
[TBL] [Abstract][Full Text] [Related]
18. Nurses' perceptions of antiemetic effectiveness.
Rhodes VA; McDaniel RW; Simms SG; Johnson M
Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system side-effects of 5-HT3-receptor antagonists in elderly cancer patients treated with chemotherapy.
Tralongo P; Dimari A; Conti G; Aiello R; Mauceri G
Ann Oncol; 2004 Jun; 15(6):987-8. PubMed ID: 15151959
[No Abstract] [Full Text] [Related]
[Next] [New Search]
